Skip to content Skip to footer
Subscribe Now
NEWS

The NMPA Clears Shanghai Henlius’ IND Application of HLX17 (Biosimilar, Keytuda) for Treating Solid Tumors

Shots:  The NMPA has cleared IND application of HLX17 to conduct its clinical study in comparison with Keytruda for treating melanoma, NSCLC, esophageal cancer, HNSCC, CRC, HCC, biliary tract cancer, TNBC, MSI-H/dMMR cancer & gastric cancer   HLX17 was assessed under pharmacologic comparative trial, preclinical pharmacology study as well as PK/PD & immunogenicity studies that showed similarity…
September 2, 2024

Read more

PharmaShots Interview Purnanand Sarma, CEO of Immunome, Shares Insights on R&D Update IL-38 Targeting Antibody Treatment for Cancer
VIEWPOINTS

PharmaShots Interview: Purnanand Sarma, CEO of Immunome, Shares Insights on R&D Update IL-38 Targeting Antibody Treatment for Cancer

Shots:  Purnanand spoke about the preclinical results of lead candidate in oncology and how its identifies IL-38 as a target to treat cancer Purnanand also talked about Immunome’s collaboration with Fox Chase Cancer Center for the further development of its prime product The interview gives a understanding of Immunome’s goal of developing therapeutics to treat…
August 2, 2022

Read more

PharmaShots Interview In Conversation with Cidara’s CEO, Dr.Jeff Stein, Where he Shares Insights on the IND acceptance by the FDA to Treat Influenza
VIEWPOINTS

PharmaShots Interview: In Conversation with Cidara’s CEO, Dr.Jeff Stein, Where he Shares Insights on the IND acceptance by the FDA to Treat Influenza

Shots: Jeff spoke about IND acceptance by the US FDA for its lead flu drug-Fc conjugate immunotherapy for the prevention and treatment of Influenza He also discussed Cidara’s collaboration with Janssen Pharmaceuticals to develop and commercialize Cidara’s DFCs The interview also emphasizes Cidara’s Cloudbreak platform to develop immunotherapeutic antivirals and treatment options for influenza Smriti:…
June 6, 2022

Read more